MENLO PARK, Calif.--(BUSINESS WIRE)--July 13, 2006--Geron Corporation (Nasdaq:GERN - News) today announced the publication of novel chemical methods that reduce the number of chemical steps and cost of synthesizing the monomer building blocks of its patented N3'-P5' thiophosphoramidate oligonucleotide compounds, including its lead anti-cancer drug, GRN163L.
